Medically eligible women who do not use HAART: The importance of abuse, drug use, and race

American Journal of Public Health

Volumn 94, Issue 7, 2004, Pages 1147-1151

  Cohen, Mardge H ^a,h   Cook, Judith A ^b   Grey, Dennis ^b   Young, Mary ^c   Hanau, Lawrence H ^d   Tien, Phyllis ^e   Levine, Alexandra M ^f   Wilson, Tracey E ^g  

^a Cook Co Bureau of Health Services ^*  (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE;

ADULT; ARTICLE; CHILD SEXUAL ABUSE; CONTROLLED STUDY; DRUG ABUSE; DRUG INDICATION; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREVALENCE; RACE;

EID: 3042732190     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.94.7.1147     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2001;13(2):1-44.
2. Whitman S, Murphy J, Cohen M, Sherer R. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics young adults, and injection drug users, from 1995-1997. Arch Intern Med. 2000;160: 365-369.
3. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr. 2002;29:197-202.
4. Gange SJ, Barron Y, Greenblatt RM, et al. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health. 2002;56:153-159.
5. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002;113:91-98.
6. Cook J, Cohen MH, Grey D, et al. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health. 2002;92:82-87.
7. Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401-409.
8. Garner LI, Holmberg SD, Moore J, et al. Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care. J Acquir Immune Defic Syndr. 2002;29:69-75.
9. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology. 1998;9:117-125.
10. Women's Interagency HIV Study (WIHS) Manual of Operations. Version 4.01.03. Section 8. Baltimore, Md: WIHS Data Management and Analysis Center at Johns Hopkins Bloomberg School of Public Health: 19.
11. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-390.
12. Cohen M, Deamant C, Barkan S, et al. Domestic violence and childhood sexual abuse in women with HIV infection and women at risk for HIV. Am J Public Health. 2000;90:560-565.
13. Vlahov D, Wientge D, Moore J, et al. Violence among women with or at risk for HIV infection. AIDS Behav. 1998;2:53-60.
14. Gielen AC, McDonnell KA, Wu AW, et al. Quality of life among women living with HIV: the importance of violence, social support and self care behaviors. Soc Sci Med 2001;52:315-322.
15. Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE). Am J Prev Med. 1998;14:245-258
16. McNutt L, van Ryn M, Clark C, Frasier I. Partner violence and medical encounters: African American women's perspectives. Am J Prev Med. 2000;19: 264-269.
17. Leenerts MH. The disconnected self: consequences of abuse in a cohort of low-income white women living with HIV/AIDS. Health Care Women Int. 1999;20:381-400.
18. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999;21:114-119.
19. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and non-medical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000;23:396-404.
20. Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr. 2001;28: 345-350.
21. Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDS. 2001;15:185-191.
22. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
23. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
24. Ouimette PC, Brown PJ, Najavits LM. Course and treatment of patients with both substance use and posttraumatic stress disorders. Addict Behav. 1998;23: 785-795.
25. Institute of Medicine (IOM). Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 2001:134.
26. Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol. 2001;154: 563-573.
27. Palacio H, Khan JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002;117:233-250.
28. Healthy People 2010: Understanding and Improving Health. 2nd ed. Washington, DC: US Department of Health and Human Services; 2000.
29. Wong MD, Shapiro MF, Boscardin J, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002;347:1585-1592.